Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 3Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Disease Progression 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × brigatinib × Clear all
NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

City of Hope Medical Center

Phase 1 Active not recruiting
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

University of California, San Francisco

Phase 1 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡